Re: Pyrexia in patients treated with dabrafenib plus trametinib across clinical trials in BRAF-mutant cancers

Professor Dirk Schadendorf Pyrexia in patients treated with dabrafenib plus trametinib across clinical trials in BRAF-mutant cancersEuropean Journal of CancerVol. 153PreviewDabrafenib plus trametinib has demonstrated clinical benefit across multiple BRAF-mutant tumours, leading to approval for resected stage III and metastatic melanoma, non–small-cell lung cancer (NSCLC) and anaplastic thyroid cancer. Pyrexia is a common adverse event in patients treated with dabrafenib plus trametinib. Here, we characterise the incidence, patterns and management of pyrexia in patients receiving dabrafenib plus trametinib in clinical trials. Full-Text PDF Open AccessReply to: Letter comments on: Pyrexia in patients treated with dabrafenib plus trametinib across clinical trials in BRAF-mutant cancersEuropean Journal of CancerVol. 162PreviewOn behalf of my coauthors, I thank Dr Hersey for his insightful analysis of our manuscript describing pyrexia characteristics in patients treated with dabrafenib plus trametinib, a topic of critical importance given that pyrexia is the most common adverse event associated with this treatment combination. The goal of our manuscript was to describe pyrexia incidence and management patterns among patients who received dabrafenib plus trametinib in clinical trials. Notably, the 1076 patients included in our analysis encompassed those with advanced non-small cell lung cancer (n = 82), stage III resectable melanoma (n = 435), or unresectable/metastatic melanoma (n = 559) [1]. Full-Text PDF